Delivery Order SPE2DR25D3017-SPE2DR26F3DZ8
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp valued at $30,465.45 for Mounjaro 5 mg/0.5 ml pen injections on December 10, 2025, with a completion date of December 11, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a tirzepatide-based pharmaceutical used for diabetes management, consistent with...
- The Defense Logistics Agency awarded a delivery order valued at $4,616.23 to AmerisourceBergen Drug Corp for Mounjaro 5 mg/0.5 mL pen injections on December 9, 2025, with completion scheduled for December 10, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a tirzepatide-based medication used for diabetes management, reflecting the...
- The Defense Logistics Agency awarded a delivery order valued at $43,363.77 to AmerisourceBergen Drug Corp for the supply of Mounjaro 10 mg/0.5 mL pen injectors on November 18, 2025, with completion scheduled for November 19, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a diabetes treatment medication, consistent with...
- The Defense Logistics Agency awarded a delivery order valued at $44,586.36 to AmerisourceBergen Drug Corp for the supply of Mounjaro 10 mg/0.5 ml pen injectors on September 29, 2025. This is a firm fixed-price, non-set-aside contract with a completion date of September 30, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a tirzepatide-based diabetes medication used for glycemic control in patients with type 2 diabetes. This...
- The Defense Logistics Agency awarded a delivery order valued at $108,836.00 to AmerisourceBergen Drug Corp for the supply of Mounjaro 10 mg/0.5 ml pen injectors on September 15, 2025. This firm fixed-price contract, with an ultimate completion date of September 16, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. Mounjaro is a tirzepatide-based...
- The Defense Logistics Agency awarded a $19,091.85 delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Mounjaro 7.5 mg/0.5 mL pen injectors with an ultimate completion date of September 8, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitively awarded transaction under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). The pharmaceutical distributor,...
- The Defense Logistics Agency awarded a delivery order valued at $6,010.72 to AmerisourceBergen Drug Corp for Mounjaro 5 mg/0.5 ml pen injectors on November 12, 2025, with an ultimate completion date of November 13, 2025. This firm fixed price delivery order, with no set-aside designation, represents a competitive award under the company's larger indefinite delivery contract with DLA Troop Support Medical. The place of performance is AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $11,461.68 delivery order to AmerisourceBergen Drug Corp for Mounjaro 12.5 mg/0.5 mL pen injectors on July 14, 2025, with completion targeted for July 15, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a GLP-1 receptor agonist used in diabetes management, consistent with...
- The Defense Logistics Agency awarded a delivery order valued at $1,580.52 to AmerisourceBergen Drug Corp for the supply of Mounjaro 5 mg/0.5 mL pen injectors with an ultimate completion date of November 5, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the prime contractor. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a diabetes medication, consistent with...
- The Defense Logistics Agency awarded a $1,053.68 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Mounjaro 10 mg/0.5 mL pen auto-injectors on December 4, 2025, with completion targeted for December 5, 2025. This delivery order represents a child contract under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical product will be delivered to the...
- SPE2DR25D3017Indefinite Delivery Contract
- SPE2DR25D3017-SPE2DR26F3DZ8Delivery Order
The Defense Logistics Agency awarded a $61,157.01 delivery order to AmerisourceBergen Drug Corp for Mounjaro 5 mg/0.5 ml pen injectors on November 24, 2025, with an ultimate completion date of November 25, 2025. This competitively awarded, firm fixed-price delivery order contains no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a tirzepatide injection used for diabetes management, reflecting the company's role as a critical pharmaceutical distributor for federal medical procurement needs. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a prime vendor serving the Defense Health Agency and other federal healthcare systems, AmerisourceBergen leverages this comprehensive global pharmaceutical support vehicle to supply medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic areas to military and veteran healthcare programs worldwide. The company's extensive federal contract portfolio demonstrates its established capability to fulfill competitive pharmaceutical procurement requirements at various volume levels.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $61.2k | 11/23/25 |